A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2019
At a glance
- Drugs IMC gp100 (Primary) ; Dacarbazine; Ipilimumab; Pembrolizumab
- Indications Uveal melanoma
- Focus Therapeutic Use
- Sponsors Immunocore
- 22 Jun 2017 Status changed from not yet recruiting to recruiting.
- 11 May 2017 Planned initiation date changed from 1 Apr 2017 to 1 Jun 2017.
- 07 Mar 2017 New trial record